The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery
Steven M Silverstein,1 Mitchell A Jackson,2 Damien F Goldberg,3 Mauricio Muñoz4On behalf of the Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group1Silverstein Eye Centers, Kansas City, MO, USA; 2Jacksoneye, Inc., Lake Villa, IL, USA; 3Wolstan & Goldberg Eye Associates, To...
Guardado en:
Autores principales: | Silverstein SM, Jackson MA, Goldberg DF, Muñoz M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eb46aba2f04c46d0b93a6703d49aaf23 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan GA, et al.
Publicado: (2014) -
Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction
por: Carreño E, et al.
Publicado: (2012) -
Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen J, et al.
Publicado: (2017) -
Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
por: Shen J, et al.
Publicado: (2018) -
Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review
por: Sheppard JD
Publicado: (2016)